Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens

To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving emtricitabine (FTC) or lamivudine (3TC), administered with tenofovir disoproxil fumarate (TDF) and either efavirenz (EFV) or a ritonavir-boosted p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2012-06, Vol.67 (6), p.1475-1478
Main Authors: MARCELIN, A. G, CHARPENTIER, C, CALVEZ, V, WIRDEN, M, LANDMAN, R, VALANTIN, M. A, SIMON, A, KATLAMA, C, YENI, P, DESCAMPS, D, AUBRON-OLIVIER, C
Format: Article
Language:English
Subjects:
Adenine - administration & dosage
Adenine - analogs & derivatives
Adult
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
Biological and medical sciences
Data processing
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Deoxycytidine - pharmacology
Drug resistance
Drug Resistance, Viral
Emtricitabine
Female
France
HIV
HIV - drug effects
HIV - isolation & purification
HIV Infections - drug therapy
HIV Infections - virology
Human immunodeficiency virus
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Lamivudine - administration & dosage
Lamivudine - pharmacology
Male
Medical sciences
Middle Aged
Mutation
Mutation, Missense
Organophosphonates - administration & dosage
Pharmacology
Pharmacology. Drug treatments
Retrospective Studies
RNA, Viral - blood
Selection, Genetic
Tenofovir
Treatment Failure
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving emtricitabine (FTC) or lamivudine (3TC), administered with tenofovir disoproxil fumarate (TDF) and either efavirenz (EFV) or a ritonavir-boosted protease inhibitor (PI; lopinavir or atazanavir). Patient data held at two clinical centres in France were analysed retrospectively. Eligible patients had experienced virological suppression (plasma HIV RNA
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dks047